Related Experiment Video

Updated: May 4, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

20.8K

[Treatment outcome of peptide vaccination for advanced colorectal cancer]

Fumiaki Sugiura1, Keisuke Inoue, Akihiro Kogita

  • 1Dept. of Surgery, Kinki University Faculty of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 8, 2014
PubMed

Insights

Colorectal cancer vaccines targeting RNF43 and TOMM34 showed good tolerance and long-term survival in patients. Further studies are planned to explore broader immunological responses against multiple cancer antigens.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Colorectal cancer (CRC) remains a significant health challenge, necessitating novel therapeutic strategies.
  • Identifying specific tumor antigens for targeted immunotherapy is crucial for effective cancer treatment.
  • Human Leukocyte Antigen (HLA)-A24-restricted epitope peptides from cancer-testis antigens show promise for cancer vaccination.

Purpose of the Study:

  • To evaluate the safety and efficacy of colorectal cancer-specific peptide vaccines targeting RNF43 and TOMM34.
  • To assess the immunological responses, specifically cytotoxic T lymphocyte (CTL) activity, in patients receiving the vaccines.
  • To explore the potential for long-term survival in advanced or recurrent CRC patients treated with these peptide vaccines.

Main Methods:

  • Complementary DNA (cDNA) microarray and laser microdissection were used to identify HLA-A24-restricted epitope peptides from RNF43 and TOMM34.
  • A clinical trial was conducted involving advanced or recurrent CRC patients vaccinated with RNF43 and TOMM34 peptides combined with Uracil/Tegafur (UFT) + Leucovorin (LV).
  • Cytotoxic T lymphocyte (CTL) responses against the target peptides were monitored.

Main Results:

  • The peptide vaccines were well-tolerated, with no serious adverse events reported.
  • Patients who mounted CTL responses against RNF43 and/or TOMM34 peptides demonstrated long-term survival.
  • The study supports the potential of RNF43 and TOMM34 as targets for CRC immunotherapy.

Conclusions:

  • Peptide vaccines targeting RNF43 and TOMM34 are safe and can induce beneficial immune responses in CRC patients.
  • The presence of CTL responses correlates with improved survival outcomes in advanced or recurrent colorectal cancer.
  • Further clinical trials are warranted to investigate vaccines targeting a broader range of multiple peptides for enhanced immunogenicity.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

2.2K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K